Publications by authors named "Sharon A McCarthy"

Claim this Profile
N
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.
Gerhardt Attard, Neeraj Agarwal, Julie N Graff, Shahneen Sandhu, Eleni Efstathiou, Sharon A McCarthy

Nat Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-Metastasis Survival of Patients with High-Risk Localized and Locally Advanced Prostate Cancer Undergoing Primary Treatment in the United States: A Retrospective Study.
Stephen J Freedland, Luis Fernandes, Francesco De Solda, Nasuh Buyukkaramikli, Suneel D Mundle, Sharon A McCarthy

Target Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review.
Benjamin A Gartrell, Angaja Phalguni, Paulina Bajko, Suneel D Mundle, Sharon A McCarthy

Eur Urol Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy.
Axel S Merseburger, Neeraj Agarwal, Anders Bjartell, Hirotsugu Uemura, Alvaro Juarez Soto, Sharon A McCarthy

BJU Int· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies.
Lawrence I Karsh, Katherine B Bevans, Fred Saad, Byung Ha Chung, Stéphane Oudard, Sharon A McCarthy

Future Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
Eric J Small, Kim N Chi, Simon Chowdhury, Katherine B Bevans, Amitabha Bhaumik, Sharon A McCarthy

Eur Urol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Simon Chowdhury, Anders Bjartell, Neeraj Agarwal, Byung H Chung, Robert W Given, Sharon A McCarthy

Future Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
John Shen, Simon Chowdhury, Neeraj Agarwal, Lawrence I Karsh, Stéphane Oudard, Sharon A McCarthy

Br J Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study.
Axel S Merseburger, Neeraj Agarwal, Amitabha Bhaumik, Florence Lefresne, Laurence I Karsh, Sharon A McCarthy

Eur J Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.
Rahul Aggarwal, Joshi J Alumkal, Russell Z Szmulewitz, Celestia S Higano, Alan H Bryce, Sharon A McCarthy

Prostate Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiographic progression-free survival in the ACIS trial for prostate cancer - Authors' reply.
Fred Saad, Peter De Porre, Sabine Brookman-May, Jinhui Li, Sharon A McCarthy

Lancet Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Fred Saad, Eleni Efstathiou, Gerhardt Attard, Thomas W Flaig, Fabio Franke, Sharon A McCarthy

Lancet Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Kim N Chi, Simon Chowdhury, Anders Bjartell, Byung Ha Chung, Andrea J Pereira de Santana Gomes, Sharon A McCarthy

J Clin Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tracking implementation strategies in the randomized rollout of a Veterans Affairs national opioid risk management initiative.
Shari S Rogal, Matthew Chinman, Walid F Gellad, Maria K Mor, Hongwei Zhang, Sharon A McCarthy

Implement Sci· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis